Literature DB >> 16007132

Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1.

Yide Mei1, Wenjing Du, Yonghui Yang, Mian Wu.   

Abstract

Although Puma (p53 upregulated modulator of apoptosis) was known as a principal mediator of cell death in response to diverse apoptotic signals, the molecular mechanism underlying its proapoptotic regulation remains largely uncharacterized. Here we reported that myeloid cell leukemia-1 (Mcl-1), an anti-apoptotic member of the Bcl-2 family with a rapid turnover rate, interacts with Puma. The Puma/Mcl-1 interaction was verified by both yeast two-hybrid assay and co-immuno-precipation studies. Their binding sites were mapped to BH3 (Bcl-2 homology) domain of Puma and BH1 domain of Mcl-1, respectively. Mcl-1 and Puma was shown to colocalize at the mitochondria by immunostaining. The level of Mcl-1 was increased when coexpressed with Puma, indicating Puma is able to stabilize Mcl-1. Puma binding to Mcl-1 via its BH3 domain is the prerequisite for this effect, which is further supported by the finding that Puma mutant lacking BH3 domain no longer promotes Mcl-1 protein stability. This Puma-enhanced Mcl-1 stabilization was validated in vivo under non-overexpression conditions. We also showed that BH1 domain is essential for Mcl-1 to inhibit Puma-induced apoptosis, since Mcl-1 mutant lacking BH1 domain completely abrogates its protective function. In addition, we concluded that binding of Puma to BH1 domain of Mcl-1 is necessary, but not sufficient to prevent rapid degradation of Mcl-1. In addition to PEST (proline, glutamic acid, serine, and threonine) and BH1 domain, some additional degradation signal is expected to reside in the C-terminal region of Mcl-1. In conclusion, our results provide the first evidence that the interaction between Mcl-1 and Puma may represent a novel mechanism by which Mcl-1 prevents apoptosis by increasing its stability through binding to Puma. Oncogene (2005) 24, 7224-7237. doi:10.1038/sj.onc.1208873; published online 27 June 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007132     DOI: 10.1038/sj.onc.1208873

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Structural insights into the degradation of Mcl-1 induced by BH3 domains.

Authors:  Peter E Czabotar; Erinna F Lee; Mark F van Delft; Catherine L Day; Brian J Smith; David C S Huang; W Douglas Fairlie; Mark G Hinds; Peter M Colman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

2.  A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion.

Authors:  Hyunjoo Lee; Shabirul Haque; Jennifer Nieto; Joshua Trott; John K Inman; Steven McCormick; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

Review 3.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

4.  NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1.

Authors:  A Craxton; M Butterworth; N Harper; L Fairall; J Schwabe; A Ciechanover; G M Cohen
Journal:  Cell Death Differ       Date:  2012-02-24       Impact factor: 15.828

5.  Ubiquitin-independent degradation of antiapoptotic MCL-1.

Authors:  Daniel P Stewart; Brian Koss; Madhavi Bathina; Rhonda M Perciavalle; Kristen Bisanz; Joseph T Opferman
Journal:  Mol Cell Biol       Date:  2010-04-12       Impact factor: 4.272

6.  Bcl-X(L) is the primary mediator of p21 protection against hyperoxia-induced cell death.

Authors:  Yu-Chieh M Wu; Michael A O'Reilly
Journal:  Exp Lung Res       Date:  2010-12-04       Impact factor: 2.459

7.  Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1.

Authors:  Donatella Trivigno; Frank Essmann; Stephan M Huber; Justine Rudner
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.

Authors:  Bernhard Gillissen; Jana Wendt; Antje Richter; Anja Richter; Annika Müer; Tim Overkamp; Nina Gebhardt; Robert Preissner; Claus Belka; Bernd Dörken; Peter T Daniel
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

9.  KLF4 overexpression and apigenin treatment down regulated anti-apoptotic Bcl-2 proteins and matrix metalloproteinases to control growth of human malignant neuroblastoma SK-N-DZ and IMR-32 cells.

Authors:  Nishant Mohan; Walden Ai; Mrinmay Chakrabarti; Naren L Banik; Swapan K Ray
Journal:  Mol Oncol       Date:  2012-12-20       Impact factor: 6.603

10.  Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1.

Authors:  Stephanie Campbell; Bart Hazes; Marc Kvansakul; Peter Colman; Michele Barry
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.